IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.456
EU - Europa 15.825
AS - Asia 15.466
SA - Sud America 2.754
AF - Africa 1.465
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 21
Totale 66.025
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.224
SG - Singapore 8.502
RU - Federazione Russa 4.806
CN - Cina 3.815
IT - Italia 2.916
IE - Irlanda 2.659
UA - Ucraina 2.422
BR - Brasile 2.251
VN - Vietnam 1.178
CA - Canada 996
FR - Francia 877
CI - Costa d'Avorio 686
KR - Corea 456
GB - Regno Unito 413
IN - India 380
SE - Svezia 370
DE - Germania 362
NG - Nigeria 334
AR - Argentina 189
MX - Messico 152
BD - Bangladesh 148
PL - Polonia 146
NL - Olanda 145
SN - Senegal 143
FI - Finlandia 140
JP - Giappone 122
IQ - Iraq 115
ZA - Sudafrica 109
HK - Hong Kong 102
UZ - Uzbekistan 98
CH - Svizzera 94
TR - Turchia 90
ES - Italia 83
EC - Ecuador 80
AT - Austria 71
CZ - Repubblica Ceca 57
BE - Belgio 55
ID - Indonesia 55
PK - Pakistan 54
GR - Grecia 53
CO - Colombia 51
VE - Venezuela 49
CL - Cile 48
MA - Marocco 48
LB - Libano 43
LT - Lituania 34
SA - Arabia Saudita 34
KE - Kenya 33
JO - Giordania 32
PY - Paraguay 30
AU - Australia 29
AE - Emirati Arabi Uniti 26
IR - Iran 26
TN - Tunisia 25
EG - Egitto 24
IL - Israele 24
PH - Filippine 23
PE - Perù 21
DZ - Algeria 20
AZ - Azerbaigian 18
BJ - Benin 18
BO - Bolivia 18
EU - Europa 18
KZ - Kazakistan 18
MY - Malesia 17
RO - Romania 17
DO - Repubblica Dominicana 15
RS - Serbia 15
BG - Bulgaria 14
OM - Oman 14
UY - Uruguay 12
NO - Norvegia 11
PS - Palestinian Territory 11
SI - Slovenia 11
CR - Costa Rica 10
AL - Albania 9
HR - Croazia 9
JM - Giamaica 9
KW - Kuwait 9
PA - Panama 8
TH - Thailandia 8
ET - Etiopia 7
GT - Guatemala 7
HU - Ungheria 7
KG - Kirghizistan 7
NP - Nepal 7
NZ - Nuova Zelanda 7
TT - Trinidad e Tobago 7
HN - Honduras 6
NI - Nicaragua 6
PT - Portogallo 6
BH - Bahrain 5
SV - El Salvador 5
AO - Angola 4
BB - Barbados 4
KH - Cambogia 4
LV - Lettonia 4
MT - Malta 4
SY - Repubblica araba siriana 4
CY - Cipro 3
Totale 65.961
Salva come PNG Salva come JPEG
Città #
Dallas 5.135
Singapore 4.818
Santa Clara 2.934
Dublin 2.639
Jacksonville 2.637
San Jose 2.172
Chandler 2.134
Moscow 1.970
Ashburn 1.507
Boardman 1.117
Chicago 963
Catania 935
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Lauterbourg 707
Abidjan 684
Toronto 663
Houston 532
Los Angeles 528
Hefei 501
Seoul 456
Des Moines 423
Beijing 418
Ho Chi Minh City 390
San Mateo 386
Hanoi 268
Nanchang 263
Wilmington 262
New York 248
Council Bluffs 238
Civitanova Marche 229
São Paulo 218
Buffalo 183
Saint Petersburg 182
Shenyang 180
Hebei 176
Abuja 172
Ottawa 151
Jiaxing 148
Dakar 142
Florence 136
Changsha 135
Lagos 126
Rome 118
Orem 117
Montreal 114
Tianjin 110
Tokyo 109
Warsaw 107
Milan 103
Grafing 96
Palermo 96
Kochi 92
Hong Kong 91
Dong Ket 87
Stockholm 87
Brooklyn 81
London 74
Denver 72
Johannesburg 72
Munich 71
Seattle 69
Boston 67
Rio de Janeiro 67
Poplar 63
Chennai 62
Washington 61
Phoenix 60
Atlanta 54
San Francisco 54
Helsinki 53
Belo Horizonte 51
The Dalles 51
Amsterdam 50
Brussels 47
Columbus 47
Hangzhou 47
Mumbai 46
Tashkent 46
Lappeenranta 44
Mexico City 44
Redondo Beach 44
Turku 42
Den Haag 39
Haiphong 39
Norwalk 38
Ankara 36
Port Harcourt 36
Baghdad 35
Kunming 35
Da Nang 34
Bari 33
Frankfurt am Main 33
Paris 33
Pune 33
Falls Church 32
Elk Grove Village 31
Manchester 31
Totale 44.392
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 290
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 281
Il Rasario. Semeiotica medica 259
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 227
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 224
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 216
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 204
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 200
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 194
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 184
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 179
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 177
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 177
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 177
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 177
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 175
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 175
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 169
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 169
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 168
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 168
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 164
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 163
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 162
Hedgehog signaling pathways in multiple myeloma 160
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 160
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 160
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 159
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 159
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 159
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 158
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 158
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 157
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 157
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 156
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 155
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 154
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 154
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 153
A case of high-risk AML in a patient with advanced systemic mastocytosis 153
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 152
A snapshot of asparaginase-induced liver insufficiency. 149
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 149
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 148
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 148
Acute pre-hepatic portal thrombosis: diagnosis and therapy 147
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 147
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 147
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 147
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 146
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 146
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 146
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 146
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 144
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 142
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 142
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 142
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 141
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 141
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 140
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 140
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 139
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 139
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 139
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 139
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 138
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 138
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 137
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 137
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 137
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 137
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 137
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 137
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 137
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 136
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 136
Multiple Myeloma in 2023 Ways: From Trials to Real Life 135
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 135
Comprehensive Analysis of TSPAN32 Regulatory Networks and Their Role in Immune Cell Biology 135
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 135
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 135
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 134
Acute myeloid leukemia in elderly patients. 133
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 133
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 132
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 130
Bone turnover markers in patients with type 1 Gaucher disease 130
Eventi avversi e trigger C12: Stroke in ospedale 130
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 129
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 129
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 129
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 128
A New Method To Evaluate the Prognostic Value of Response to Prednisone Pre-Treatment in Adult (15–60 Yrs) Patients with Acute Lymphoblastic Leukemia: Results of the GIMEMA LAL 2000 Study 128
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 127
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 127
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 126
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 126
Terapia del mieloma multiplo 126
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 126
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 126
Totale 15.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 224.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 224.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021608 0 0 0 0 0 0 0 0 0 0 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202628.167 1.673 1.754 5.013 1.882 4.775 5.439 3.920 613 1.547 1.520 31 0
Totale 67.083